Another weapon in the anti COVID armoury, VIR7831. Despite its anonymous sounding name the drug has real promise as an early treatment for symptomatic patients at high risk for severe COVID. Trial results to date have spurred GSK to stop recruiting and apply to have the drug authorised in the US and elsewhere.
The antibody, VIR7831, is said to bind to a highly conserved epitope of the spike protein of the virus, making it effective against variants.
They need to hurry up and approve it; sounds awesome!
I found the following part to be most interesting in another coverage of the same:
Monoclonal antibodies may play a key role in protecting people less responsive to vaccines or unable to be inoculated against SARS-CoV-2 such as cancer patients who have more suppressed immune systems.
bloomberg.com/news/articles...
However, it seems like this is seeking approval as a treatment post covid infection, and not as a prophylactic (vaccine).
Guess we need to wait and watch how the decisions are made regarding cancer patients and other immune suppressed populations...
Updated Guidance for U.K. people at higher risk with COVID
MABs - Encouraging, but not really
V&O Update - After 6 months
